Eloxx Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Eloxx Pharmaceuticals Inc (ELOX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Eloxx Pharmaceuticals Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Eloxx Pharmaceuticals Inc | - | - | - | Yes |
| Competitors combined (16) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ELOX Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Amicus Therapeutics inc | 282.9% | Outperformed |
| 2 | Arcellx Inc | 282.9% | Outperformed |
| 3 | Biogen Inc | 282.9% | Outperformed |
| 4 | Vertex Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Gilead Sciences Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Eloxx Pharmaceuticals Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Eloxx Pharmaceuticals Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Eloxx Pharmaceuticals Inc | 3.75 | - |
| Gilead Sciences Inc | 189,197.03 | 30,457.00 |
| Vertex Pharmaceuticals Inc | 134,661.38 | 12,587.20 |
| Biogen Inc | 33,937.60 | 9,937.40 |
| Biomarin Pharmaceutical Inc | 11,563.01 | 3,406.61 |
| Arcellx Inc | 6,479.07 | 22.29 |
| SUBTOTAL | 395,062.14 | 62,036.90 |
Sign in to see all competitors of Eloxx Pharmaceuticals Inc .
Sources: Eloxx Pharmaceuticals Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Eloxx Pharmaceuticals Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Eloxx Pharmaceuticals Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Biogen Inc | Reportable 100.00 % |
| Biomarin Pharmaceutical Inc | Reportable 100.00 % |
| Ptc Therapeutics inc | Life Science Segment 100.00 % |
| Sarepta Therapeutics Inc | All Other Segments 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Eloxx Pharmaceuticals Inc .
Eloxx Pharmaceuticals Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Eloxx Pharmaceuticals Inc | 4 | - | -2,048,200 |
| Gilead Sciences Inc | 189,197 | 1,791,588 | -190,588 |
| Vertex Pharmaceuticals Inc | 134,661 | 31,079,506 | 10,877,037 |
| Biogen Inc | 33,938 | 1,324,987 | 182,920 |
| Biomarin Pharmaceutical Inc | 11,563 | 1,057,626 | 22,655 |
| Arcellx Inc | 6,479 | 106,632 | -1,095,378 |
| PEERS TOTAL | 395,058 | 1,784,054 | 40,048 |
Sign in to see all peers for Eloxx Pharmaceuticals Inc .
Eloxx Pharmaceuticals Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 70.78 % |
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Ptc Therapeutics inc | All Other Countries Other Than Russia Brazil and United States 16.36 % |
| Ultragenyx Pharmaceutical Inc | North America 43.38 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Eloxx Pharmaceuticals Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Eloxx Pharmaceuticals Inc's industry classification, broader than the peer set above. Market cap in millions of $.Eloxx Pharmaceuticals Inc ranks #0 of 159 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,326, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 227,463 | 25.80 % |
| 2 | Gilead Sciences Inc | 189,197 | 21.46 % |
| 3 | Moderna Inc | 78,517 | 8.91 % |
| 4 | Argenx Se | 64,197 | 7.28 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 0 | Eloxx Pharmaceuticals Inc | 66 | 0.00 % |
Market cap and industry share for the rest of Eloxx Pharmaceuticals Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Eloxx Pharmaceuticals Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | - | 21.3x | - |
| P/B | -0.1x | 5.1x | -5.2x |
| Return on Equity | 24.21 % | industry aggregate | 10.71 % |
| Return on Invested Capital | 17.22 % | -6.17 % (avg) | 23.39 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Eloxx Pharmaceuticals Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | -84.60 % | - | -56.70 % | -51.64 % | -57.99 % | -113.38 % | -353.31 % | 20.82 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Eloxx Pharmaceuticals Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,326 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Eloxx Pharmaceuticals Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Eloxx Pharmaceuticals Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Eloxx Pharmaceuticals Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 10.7 points above the industry aggregate.
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-5.4% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Eloxx Pharmaceuticals Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Eloxx Pharmaceuticals Inc | 0.38 | 0.43 | - |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Biogen Inc | - | 2.74 | 0.35 |
| Biomarin Pharmaceutical Inc | 1.41 | 4.08 | 0.30 |
| Arcellx Inc | 0.66 | 4.27 | - |
Sign in to see all peers for Eloxx Pharmaceuticals Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Eloxx Pharmaceuticals Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Eloxx Pharmaceuticals Inc | Q1 2026 | - | - |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Biogen Inc | Q1 2026 | +1.9 % | +32.8 % |
| Biomarin Pharmaceutical Inc | Q2 2026 | +19.9 % | -81.4 % |
| Arcellx Inc | Q4 2025 | -89.2 % | - |
| PEERS TOTAL | +12.4 % | - |
Sign in to see all peers for Eloxx Pharmaceuticals Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Eloxx Pharmaceuticals Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Eloxx Pharmaceuticals Inc | Q1 2026 | - | - |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Biogen Inc | Q1 2026 | +5.0 % | +8.7 % |
| Biomarin Pharmaceutical Inc | Q2 2026 | +35.1 % | +97.2 % |
| Arcellx Inc | Q4 2025 | - | -49.0 % |
Sign in to see all peers for Eloxx Pharmaceuticals Inc .
Eloxx Pharmaceuticals Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Eloxx Pharmaceuticals Inc | - | - | - |
| Gilead Sciences Inc | - | - | - |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Biogen Inc | 4.71% | 5.23% | 7.54% |
| Biomarin Pharmaceutical Inc | 0.82% | 0.91% | 1.18% |
| Arcellx Inc | - | - | - |
Sign in to see all peers for Eloxx Pharmaceuticals Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Eloxx Pharmaceuticals Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Eloxx Pharmaceuticals Inc | - | - |
| Gilead Sciences Inc | - | 6.21 |
| Vertex Pharmaceuticals Inc | 30.77 | 10.70 |
| Biogen Inc | 24.53 | 3.42 |
| Biomarin Pharmaceutical Inc | 165.17 | 3.39 |
| Arcellx Inc | - | 290.72 |
| PEERS AVERAGE | 287.93 | 6.37 |
Sign in to see all peers for Eloxx Pharmaceuticals Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.